TY - JOUR
T1 - Multicenter Diagnostic Evaluation of a Novel Coronavirus Antigen Lateral Flow Test among Symptomatic Individuals in Brazil and the United Kingdom
AU - LSTM Diagnostic Group
AU - Body, Richard
AU - Dark, Paul
AU - Reynard, Charles
PY - 2022/12/1
Y1 - 2022/12/1
N2 - The COVID-19 pandemic has led to the commercialization of many antigen-based rapid diagnostic tests (Ag-RDTs), requiring independent evaluations. This report describes the clinical evaluation of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom. The collected samples (446 nasal swabs from Brazil and 246 nasopharyngeal samples from the UK) were analyzed by the Ag-RDT and compared to reverse transcription-quantitative PCR (RT-qPCR). Analytical evaluation of the Ag-RDT was performed using direct culture supernatants of SARS-CoV-2 strains from the wild-type (B.1), Alpha (B.1.1.7), Delta (B.1.617.2), Gamma (P.1), and Omicron (B.1.1.529) lineages. An overall sensitivity and specificity of 88.2% (95% confidence interval [CI], 81.3 to 93.3) and 100.0% (95% CI, 99.1 to 100.0), respectively, were obtained for the Brazilian and UK cohorts. The analytical limit of detection was determined as 1.0 × 10
3 PFU/mL (Alpha), 2.5 × 10
2 PFU/mL (Delta), 2.5 × 10
3 PFU/mL (Gamma), and 1.0 × 10
3 PFU/mL (Omicron), giving a viral copy equivalent of approximately 2.1 × 10
4 copies/mL, 9.0 × 10
5 copies/mL, 1.7 × 10
6 copies/mL, and 1.8 × 10
5 copies/mL for the Ag-RDT, respectively. Overall, while a higher sensitivity was claimed by the manufacturers than that found in this study, this evaluation finds that the Ag-RDT meets the WHO minimum performance requirements for sensitivity and specificity of COVID-19 Ag-RDTs. This study illustrates the comparative performance of the Hotgen Ag-RDT across two global settings and considers the different approaches in evaluation methods.
AB - The COVID-19 pandemic has led to the commercialization of many antigen-based rapid diagnostic tests (Ag-RDTs), requiring independent evaluations. This report describes the clinical evaluation of the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) (Beijing Hotgen Biotech Co., Ltd.), at two sites within Brazil and one in the United Kingdom. The collected samples (446 nasal swabs from Brazil and 246 nasopharyngeal samples from the UK) were analyzed by the Ag-RDT and compared to reverse transcription-quantitative PCR (RT-qPCR). Analytical evaluation of the Ag-RDT was performed using direct culture supernatants of SARS-CoV-2 strains from the wild-type (B.1), Alpha (B.1.1.7), Delta (B.1.617.2), Gamma (P.1), and Omicron (B.1.1.529) lineages. An overall sensitivity and specificity of 88.2% (95% confidence interval [CI], 81.3 to 93.3) and 100.0% (95% CI, 99.1 to 100.0), respectively, were obtained for the Brazilian and UK cohorts. The analytical limit of detection was determined as 1.0 × 10
3 PFU/mL (Alpha), 2.5 × 10
2 PFU/mL (Delta), 2.5 × 10
3 PFU/mL (Gamma), and 1.0 × 10
3 PFU/mL (Omicron), giving a viral copy equivalent of approximately 2.1 × 10
4 copies/mL, 9.0 × 10
5 copies/mL, 1.7 × 10
6 copies/mL, and 1.8 × 10
5 copies/mL for the Ag-RDT, respectively. Overall, while a higher sensitivity was claimed by the manufacturers than that found in this study, this evaluation finds that the Ag-RDT meets the WHO minimum performance requirements for sensitivity and specificity of COVID-19 Ag-RDTs. This study illustrates the comparative performance of the Hotgen Ag-RDT across two global settings and considers the different approaches in evaluation methods.
KW - Ag-RDT
KW - COVID-19
KW - LFA
KW - SARS-CoV-2
KW - diagnostics
UR - http://europepmc.org/abstract/med/36448777
U2 - 10.1128/spectrum.02012-22
DO - 10.1128/spectrum.02012-22
M3 - Article
C2 - 36448777
SN - 2165-0497
VL - 10
SP - e0201222
JO - Microbiology spectrum
JF - Microbiology spectrum
IS - 6
ER -
